Chemed

CHE on NYSE. Chemed sells hospice care and plumbing services to patients and homeowners. Market value $6.7bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Worth a closer look

Read what could go wrong

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
4.9%fair

For every $100 of what the whole company costs, it produced $4.86 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
19.4×full

You pay 19.4 years of operating profit for the business. The average large US company costs around 18.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 75 of 100. Price score: 69 of 100. Our list needs 70 on quality and 60 on price.

$509.84 a share, 40% above its 1-year low

Over the past year the price has ranged from $365.21 to $557.00.

Dividend: 0.5% a year

Paid every year for at least 5 years

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

0.2
0.3
0.3
0.4
0.3
0.3
2021202220232024202512 monthsto Jun '26
Revenue
$2.1bn$2.1bn$2.3bn$2.4bn$2.5bn
Operating margin
16.0%16.1%15.0%15.1%13.4%
Debt to equity
0.300.12n/an/an/a
Shares outstanding
0.01bn0.02bn0.01bn0.01bn0.01bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)5 of 7 checks we could run
  • Profit backed by cash (accruals)Yes
  • DebtUnknown
  • Revenue growth, five yearsSlow, 4.0% a year
  • Buying back its own sharesYes, 12% fewer since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $673 million last quarter, up 9% on a year ago.
  • Profit: $68 million, up 29% on a year ago.
  • It keeps 13 cents of each $1 of sales as operating profit, down from 15 cents a year earlier.
  • Spare cash over the past 12 months: $324 million, down from $371 million.
  • 10% fewer shares than a year ago. Each share owns a bit more of the company.
  • Sales grew on a year ago in 3 of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$606m
December 2024$640m
March 2025$647m
June 2025$619m
September 2025$625m
December 2025$639m
March 2026$658m
June 2026$673m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024$76m
December 2024$90m
March 2025$72m
June 2025$52m
September 2025$64m
December 2025$77m
March 2026$66m
June 2026$68m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
27 February 2026
Next quarterly (estimated, 10-Q)
30 October 2026

Who owns it

4 long-term investors we follow own it, up from 3 last quarter. 530 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

3 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 5 sold $9m.

  • MCNAMARA KEVIN J
    president and CEO, Director
    Sold
    Date
    28 September 2026
    Shares
    2,000
    Price
    $513.45
    Value
    $1m
  • MCNAMARA KEVIN J
    president and CEO, Director
    Sold
    Date
    18 September 2026
    Shares
    2,000
    Price
    $501.40
    Value
    $1m
  • LEE SPENCER S
    executive vice president
    Sold
    Date
    21 August 2026
    Shares
    1,000
    Price
    $541.04
    Value
    $541,040
  • MCNAMARA KEVIN J
    president and CEO, Director
    Sold
    Date
    21 August 2026
    Shares
    2,000
    Price
    $541.16
    Value
    $1m
  • MCNAMARA KEVIN J
    president and CEO, Director
    Sold
    Date
    3 August 2026
    Shares
    2,000
    Price
    $539.51
    Value
    $1m
  • GRACE PATRICK P
    Director
    Sold
    Date
    31 July 2026
    Shares
    190
    Price
    $532.00
    Value
    $101,080
  • LINDELL ANDREA R
    Director
    Sold
    Date
    9 June 2026
    Shares
    1,347
    Price
    $447.33
    Value
    $602,554
  • WALSH GEORGE J III
    Director
    Sold
    Date
    29 May 2026
    Shares
    500
    Price
    $437.83
    Value
    $218,915
  • GRACE PATRICK P
    Director
    Sold
    Date
    8 May 2026
    Shares
    60
    Price
    $425.78
    Value
    $25,547
  • MCNAMARA KEVIN J
    president and CEO, Director
    Sold
    Date
    1 May 2026
    Shares
    2,000
    Price
    $421.13
    Value
    $842,260

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 27 Feb 2026, plus the 10-Q filed 31 Jul 2026 and 4 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

What changed in the risks this year

Companies must list what could hurt them each year. These are the parts that changed since last year’s report.

  • Significant Tariffs Could Increase Costs, Decrease Margin, and Materially Adversely Affect the Business.

    Could happen
    Both Roto-Rooter’s and VITAS’s primary businesses are the provision of services within the United States. Accordingly, they are likely to be less affected by the impact of specific or wide-ranging tariffs than many other entities in the United States and Global economies. However, significant tariffs on certain products, such as steel for Roto-Rooter’s cabling machines and pharmaceuticals utilized by VITAS, could materially increase the costs of Roto-Rooter and VITAS. Additionally, because our service businesses heavily rely on delivering service to customers or patients in their residences, increases in the costs of vehicle acquisition, maintenance, repair, and reimbursement for employees’ use of personal vehicles, could have a significant increase on our expenses.
    Read more
  • Significant Tariffs Could Increase Costs, Decrease Margin, and Materially Adversely Affect the Business.

    Could happen
    If, as a result of tariffs, the United States’ economy experiences a recession or other economic slowdown, the demand for Roto-Rooter’s non-emergency services may decline materially.
  • Liability claims may have an adverse effect on VITAS, and its insurance coverage may be inadequate.

    Already happened
    Despite significant safeguards, including active intrusion protection, firewalls and virus detection software, as discussed in greater detail on Item 1C below, in October of 2025, access to our systems was gained by a threat actor in a cybersecurity attack. The threat actor was able to access a significant amount of Protected Health Information (“PHI”); however, despite repeated attempts, was not able to insert a tool often used by threat actors into our system. Our response plan was effective in identifying, quarantining, and eliminating the third-party intrusion, but not before access to PHI was gained.
    Read more
  • Significant Tariffs Could Increase Costs, Decrease Margin, and Materially Adversely Affect the Business.

    Could happen
    To the extent that tariffs cause any adverse impacts on global supply chains, it could further materially affect the ability of both businesses to timely source critical supplies, which may affect our delivery of services.
  • Significant Tariffs Could Increase Costs, Decrease Margin, and Materially Adversely Affect the Business.

    Could happen
    These additional costs, in the case of VITAS, cannot be passed along to our patients because of the structure of hospice reimbursement, and in the case of Roto-Rooter, may not be able to be fully passed along to our customers. These additional costs could materially adversely affect our margins.
    Read more

Read it in the annual report

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.